Compare RXT & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXT | LRMR |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.5M | 455.8M |
| IPO Year | 2020 | 2014 |
| Metric | RXT | LRMR |
|---|---|---|
| Price | $0.95 | $5.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $1.71 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 7.4M | 2.0M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.13 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,685,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.35 | $1,816.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $1.61 |
| 52 Week High | $2.74 | $6.42 |
| Indicator | RXT | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 34.31 | 57.54 |
| Support Level | $0.39 | $3.14 |
| Resistance Level | $1.22 | $5.37 |
| Average True Range (ATR) | 0.16 | 0.31 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 4.93 | 90.66 |
Rackspace Technology Inc is an end-to-end, hybrid, multi-cloud technology services company. It designs, builds, and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services, Data, Colocation, Cloud, Managed Hosting, Professional Services, and Security and Compliance. It has two reportable segments: Private Cloud and Public Cloud. Maximum revenue is generated from the Public Cloud segment, which offers cloud solutions through managed services, elastic engineering, and professional services offerings for customer environments hosted on the AWS, Microsoft Azure, and Google Cloud public cloud platforms. Geographically, the company derives its key revenue from the U.S.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.